---
document_datetime: 2025-12-02 06:26:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/entecavir-accord.html
document_name: entecavir-accord.html
version: success
processing_time: 0.1270034
conversion_datetime: 2025-12-26 10:06:26.721907
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Entecavir Accord

[RSS](/en/individual-human-medicine.xml/67110)

##### Authorised

This medicine is authorised for use in the European Union

entecavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Entecavir Accord](#news-on)
- [More information on Entecavir Accord](#more-information-on-entecavir-accord-1538)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Entecavir Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Entecavir Accord.

For practical information about using Entecavir Accord, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Entecavir Accord and what is it used for?

Entecavir Accord is a medicine used to treat chronic (long-term) hepatitis B (an infectious disease of the liver, caused by the hepatitis B virus).

It is used in adults with signs of ongoing liver injury (such as inflammation and fibrosis) when the liver is still working properly (compensated liver disease) and also when the liver is no longer working properly (decompensated liver disease).

It can also be considered for children aged from 2 to 18 years but only in those with compensated liver disease.

Entecavir Accord contains the active substance entecavir and is a 'generic medicine'. This means that Entecavir Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Baraclude.

## How is Entecavir Accord used?

Entecavir Accord can only be obtained with a prescription and is available as tablets (0.5 mg and 1 mg). Treatment with Entecavir Accord should be started by a doctor with experience in the management of chronic hepatitis B.

Entecavir Accord is taken once a day. For adults with compensated liver disease, the dose depends on whether or not the patient has been previously treated with a medicine in the same group as Entecavir Accord (a nucleoside analogue, such as lamivudine). Patients who have not been treated before with a nucleoside analogue receive a 0.5 mg dose, while those who have received lamivudine before but whose infection is no longer responding to it are given a 1 mg dose. The 0.5 mg dose can be taken with or without food, but the 1 mg dose must be taken at least 2 hours before or 2 hours after a meal. The treatment duration is determined by how the patient responds.

The 1 mg daily dose is also used in adults with decompensated liver disease and stopping treatment is not recommended in these patients.

When treatment is considered appropriate in children, the dose depends on their body weight. Children weighing 32.6 kg and above can be given the 0.5 mg tablets, while an oral solution of entecavir may be available for children weighing less than 32.6 kg. For further information, see the package leaflet.

## How does Entecavir Accord work?

The active substance in Entecavir Accord, entecavir, is an antiviral belonging to the class of the nucleoside analogues. Entecavir interferes with the action of a viral enzyme, DNA polymerase, which is involved in the formation of viral DNA. Entecavir stops the virus making DNA, and prevents it from multiplying and spreading.

## How has Entecavir Accord been studied?

Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Baraclude, and do not need to be repeated for Entecavir Accord.

As for every medicine, the company provided studies on the quality of Entecavir Accord. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Entecavir Accord?

Because Entecavir Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Entecavir Accord approved?

The European Medicines Agency concluded that, in accordance with EU requirements, Entecavir Accord has been shown to have comparable quality and to be bioequivalent to Baraclude. Therefore, the Agency's view was that, as for Baraclude, the benefit outweighs the identified risk. The Agency recommended that Entecavir Accord be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Entecavir Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Entecavir Accord have been included in the summary of product characteristics and the package leaflet.

## Other information about Entecavir Accord

The European Commission granted a marketing authorisation valid throughout the European Union for Entecavir Accord on 26 September 2017.

For more information about treatment with Entecavir Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Entecavir Accord : EPAR - Summary for the public

English (EN) (93.1 KB - PDF)

**First published:** 26/01/2018

**Last updated:** 26/01/2018

[View](/en/documents/overview/entecavir-accord-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-71)

български (BG) (119.86 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/bg/documents/overview/entecavir-accord-epar-summary-public_bg.pdf)

español (ES) (93.09 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/es/documents/overview/entecavir-accord-epar-summary-public_es.pdf)

čeština (CS) (123.08 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/cs/documents/overview/entecavir-accord-epar-summary-public_cs.pdf)

dansk (DA) (92.13 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/da/documents/overview/entecavir-accord-epar-summary-public_da.pdf)

Deutsch (DE) (94.46 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/de/documents/overview/entecavir-accord-epar-summary-public_de.pdf)

eesti keel (ET) (91.61 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/et/documents/overview/entecavir-accord-epar-summary-public_et.pdf)

ελληνικά (EL) (121.9 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/el/documents/overview/entecavir-accord-epar-summary-public_el.pdf)

français (FR) (93.72 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/fr/documents/overview/entecavir-accord-epar-summary-public_fr.pdf)

hrvatski (HR) (111.51 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/hr/documents/overview/entecavir-accord-epar-summary-public_hr.pdf)

italiano (IT) (92.12 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/it/documents/overview/entecavir-accord-epar-summary-public_it.pdf)

latviešu valoda (LV) (114.79 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/lv/documents/overview/entecavir-accord-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (114.38 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/lt/documents/overview/entecavir-accord-epar-summary-public_lt.pdf)

magyar (HU) (112.62 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/hu/documents/overview/entecavir-accord-epar-summary-public_hu.pdf)

Malti (MT) (128.31 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/mt/documents/overview/entecavir-accord-epar-summary-public_mt.pdf)

Nederlands (NL) (92.39 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/nl/documents/overview/entecavir-accord-epar-summary-public_nl.pdf)

polski (PL) (118.05 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/pl/documents/overview/entecavir-accord-epar-summary-public_pl.pdf)

português (PT) (92.6 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/pt/documents/overview/entecavir-accord-epar-summary-public_pt.pdf)

română (RO) (114.85 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/ro/documents/overview/entecavir-accord-epar-summary-public_ro.pdf)

slovenčina (SK) (116.78 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/sk/documents/overview/entecavir-accord-epar-summary-public_sk.pdf)

slovenščina (SL) (110.45 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/sl/documents/overview/entecavir-accord-epar-summary-public_sl.pdf)

Suomi (FI) (92.08 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/fi/documents/overview/entecavir-accord-epar-summary-public_fi.pdf)

svenska (SV) (92.34 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/sv/documents/overview/entecavir-accord-epar-summary-public_sv.pdf)

## Product information

Entecavir Accord : EPAR - Product Information

English (EN) (440.95 KB - PDF)

**First published:** 26/01/2018

**Last updated:** 24/07/2024

[View](/en/documents/product-information/entecavir-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-545)

български (BG) (546.33 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/bg/documents/product-information/entecavir-accord-epar-product-information_bg.pdf)

español (ES) (493.13 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/es/documents/product-information/entecavir-accord-epar-product-information_es.pdf)

čeština (CS) (479.73 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/cs/documents/product-information/entecavir-accord-epar-product-information_cs.pdf)

dansk (DA) (487 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/da/documents/product-information/entecavir-accord-epar-product-information_da.pdf)

Deutsch (DE) (519.63 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/de/documents/product-information/entecavir-accord-epar-product-information_de.pdf)

eesti keel (ET) (455 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/et/documents/product-information/entecavir-accord-epar-product-information_et.pdf)

ελληνικά (EL) (525.32 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/el/documents/product-information/entecavir-accord-epar-product-information_el.pdf)

français (FR) (519.04 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/fr/documents/product-information/entecavir-accord-epar-product-information_fr.pdf)

hrvatski (HR) (484.82 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/hr/documents/product-information/entecavir-accord-epar-product-information_hr.pdf)

íslenska (IS) (486.73 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/is/documents/product-information/entecavir-accord-epar-product-information_is.pdf)

italiano (IT) (453.6 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/it/documents/product-information/entecavir-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (525.18 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/lv/documents/product-information/entecavir-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (478.86 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/lt/documents/product-information/entecavir-accord-epar-product-information_lt.pdf)

magyar (HU) (488.73 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/hu/documents/product-information/entecavir-accord-epar-product-information_hu.pdf)

Malti (MT) (569.95 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/mt/documents/product-information/entecavir-accord-epar-product-information_mt.pdf)

Nederlands (NL) (486.13 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/nl/documents/product-information/entecavir-accord-epar-product-information_nl.pdf)

norsk (NO) (467.9 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/no/documents/product-information/entecavir-accord-epar-product-information_no.pdf)

polski (PL) (516.75 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/pl/documents/product-information/entecavir-accord-epar-product-information_pl.pdf)

português (PT) (492.49 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/pt/documents/product-information/entecavir-accord-epar-product-information_pt.pdf)

română (RO) (500.22 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/ro/documents/product-information/entecavir-accord-epar-product-information_ro.pdf)

slovenčina (SK) (482.46 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/sk/documents/product-information/entecavir-accord-epar-product-information_sk.pdf)

slovenščina (SL) (494.13 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/sl/documents/product-information/entecavir-accord-epar-product-information_sl.pdf)

Suomi (FI) (446.05 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/fi/documents/product-information/entecavir-accord-epar-product-information_fi.pdf)

svenska (SV) (469.1 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

24/07/2024

[View](/sv/documents/product-information/entecavir-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0011 01/07/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Entecavir Accord : EPAR - All Authorised presentations

English (EN) (16.02 KB - PDF)

**First published:** 26/01/2018

**Last updated:** 26/01/2018

[View](/en/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-771)

български (BG) (36.68 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/bg/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.05 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/es/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.7 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/cs/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.03 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/da/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.72 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/de/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.6 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/et/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.01 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/el/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (17.16 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/fr/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.79 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/hr/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (22.96 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/is/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.45 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/it/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.33 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/lv/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.85 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/lt/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (22.63 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/hu/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.48 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/mt/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.07 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/nl/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.77 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/no/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (25.09 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/pl/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.22 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/pt/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (32.35 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/ro/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.6 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/sk/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (17.3 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/sl/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.21 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/fi/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.09 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

26/01/2018

[View](/sv/documents/all-authorised-presentations/entecavir-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Entecavir Accord Active substance Entecavir International non-proprietary name (INN) or common name entecavir Therapeutic area (MeSH) Hepatitis B, Chronic Anatomical therapeutic chemical (ATC) code J05AF10

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Entecavir Accord is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:

- compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
- decompensated liver disease.

For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.

Entecavir Accord is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to &lt;18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients.

## Authorisation details

EMA product number EMEA/H/C/004458

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 19/07/2017 Marketing authorisation issued 25/09/2017 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Entecavir Accord : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (116.74 KB - PDF)

**First published:** 24/07/2024

[View](/en/documents/procedural-steps-after/entecavir-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Entecavir Accord : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (157.45 KB - PDF)

**First published:** 13/11/2018

**Last updated:** 24/07/2024

[View](/en/documents/procedural-steps-after/entecavir-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Entecavir Accord : EPAR - Public assessment report

Reference Number: EMA/520001/2017

English (EN) (417.16 KB - PDF)

**First published:** 26/01/2018

**Last updated:** 26/01/2018

[View](/en/documents/assessment-report/entecavir-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Entecavir Accord

Adopted

Reference Number: EMA/CHMP/367264/2017

English (EN) (75.1 KB - PDF)

**First published:** 21/07/2017

**Last updated:** 21/07/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-entecavir-accord_en.pdf)

#### News on Entecavir Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2017) 21/07/2017

#### More information on Entecavir Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/07/2024

## Share this page

[Back to top](#main-content)